Facebook Icon Print Created with Sketch. Twitter Icon Created with Sketch. Created with Sketch. LinkedIn Icon Green Check Icon Created with Sketch. YouTube Icon Right Arrow Icon Mobile Menu Icon Chevron Right Icon Phone Icon Health Study Area: AutoImmune Disease Health Study Area: Blood Cancer Health Study Area: Cardiovascular Disease Health Study Area: Fibrosis Health Study Area: Gastrointestinal Cancer Health Study Area: Genitourinary Health Study Area: Head and Neck Cancer Health Study Area: Lung Cancer Health Study Area: Melanoma Health Study Area: Women's Cancer Health Study Area: Breast Cancer For Caregivers For Clinicians Communities FAQs For Parents For Patients Chevron Icon Bookmark Icon Map Icon Share Icon Direction Arrow Icon Direction Arrow Icon Page Icon Location Icon Search Icon External Link Icon Help Icon Error Icon Glossary Email Icon Gender Both Gender Male Gender Female Created with Sketch. Created with Sketch. Health Study Area: NASH

Please Log In/Join Now first, and then use this function!


An Investigational Immuno-therapy Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Solid Cancers That Are Advanced or Have Spread - CA020-002

Updated: 10 May, 2021   |   ClinicalTrials.gov

Print Friendly Summary

Print this page and the trial guide to help you talk with your doctor.
Use the Study Participant's Guide to navigate the process of participating in a clinical trial. Understand key factors to consider before deciding and get questions to ask your healthcare team.

Trial Details

  • Phase 1/Phase 2


  • Gender(s)

  • 18+

    Age Range

  • 3


  • Recruiting

Treatment Options

Study Arms
Experimental: Part 1A: Dose Escalation Monotherapy (BMS-986207)
Drug: BMS-986207
Experimental: Part 1B: Dose Escalation Combination Therapy (BMS-986207 + nivolumab)
Biological: Nivolumab Drug: BMS-986207
Experimental: Part 1C: Triplet Cohort (BMS-986207 + nivolumab + ipilimumab)
Biological: Ipilimumab Drug: BMS-986207 Biological: Nivolumab
Experimental: Part 2A: Expansion Monotherapy (BMS-986207)
Drug: BMS-986207
Experimental: Part 2B: Expansion Combination Therapy (BMS-986207 + nivolumab)
Biological: Nivolumab Drug: BMS-986207
Experimental: Part 2C: Triplet Expansion (BMS-986207 + nivolumab + ipilimumab)
Drug: BMS-986207 Biological: Ipilimumab Biological: Nivolumab

Key Eligibility Criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Participant must consent for pretreatment and on treatment tumor biopsy samples - For Part 1C tumor biopsies are optional - Nonsmall cell lung cancer (NSCLC) without prior treatment in the advanced or metastatic setting (Part 2C) - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 - Must have received, and progressed or been intolerant to, at least 1 standard treatment regimen in the advanced or metastatic setting (Part 1A, 1B and 1C) - Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria; radiographic tumor assessment performed within 28 days before randomization Exclusion Criteria: - Primary central nervous system (CNS) disease, or tumors with CNS metastases as the only site of disease. Controlled brain metastases will be allowed to enroll - Other active malignancy requiring concurrent intervention - Uncontrolled/significant heart disease - History of chronic hepatitis [except for hepatocellular carcinoma (HCC)] - Active, known, or suspected autoimmune disease Other protocol defined inclusion/exclusion criteria apply

We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information

Have questions? Email Us

Have questions?
Email Us